| 1. |
- Thomas, HS, et al.
(författare)
-
- 2019
-
swepub:Mat__t
|
|
| 2. |
|
|
| 3. |
- Sen, P, et al.
(författare)
-
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
- 2023
-
Ingår i: Rheumatology (Oxford, England). - : Oxford University Press (OUP). - 1462-0332 .- 1462-0324. ; 62:10, s. 3291-3301
-
Tidskriftsartikel (refereegranskat)abstract
- ObjectiveCOVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys.MethodsThe first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups.ResultsWe analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs – OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs – OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7–10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8–0.97)].ConclusionVaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Ghail, Richard C., et al.
(författare)
-
EnVision : taking the pulse of our twin planet
- 2012
-
Ingår i: Experimental astronomy. - : Springer Science and Business Media LLC. - 0922-6435 .- 1572-9508. ; 33:2-3, s. 337-363
-
Tidskriftsartikel (refereegranskat)abstract
- EnVision is an ambitious but low-risk response to ESA's call for a medium-size mission opportunity for a launch in 2022. Venus is the planet most similar to Earth in mass, bulk properties and orbital distance, but has evolved to become extremely hostile to life. EnVision's 5-year mission objectives are to determine the nature of and rate of change caused by geological and atmospheric processes, to distinguish between competing theories about its evolution and to help predict the habitability of extrasolar planets. Three instrument suites will address specific surface, atmosphere and ionosphere science goals. The Surface Science Suite consists of a 2.2 m(2) radar antenna with Interferometer, Radiometer and Altimeter operating modes, supported by a complementary IR surface emissivity mapper and an advanced accelerometer for orbit control and gravity mapping. This suite will determine topographic changes caused by volcanic, tectonic and atmospheric processes at rates as low as 1 mm a (-aEuro parts per thousand 1). The Atmosphere Science Suite consists of a Doppler LIDAR for cloud top altitude, wind speed and mesospheric structure mapping, complemented by IR and UV spectrometers and a spectrophotopolarimeter, all designed to map the dynamic features and compositions of the clouds and middle atmosphere to identify the effects of volcanic and solar processes. The Ionosphere Science Suite uses a double Langmiur probe and vector magnetometer to understand the behaviour and long-term evolution of the ionosphere and induced magnetosphere. The suite also includes an interplanetary particle analyser to determine the delivery rate of water and other components to the atmosphere.
|
|
| 9. |
|
|
